Physician

Adnan A Javaid, M.D.

According to 2025 Medicare claims, Adnan Javaid, M.D. (NPI: 1881879310) practices pulmonary disease in the Winston-Salem, NC market, with the plurality of this provider's patient population coming from Forsyth, NC. This provider's primary affiliated billing organization is LUNG AND SLEEP WELLNESS CENTER PC (NPI: 1366790594; TIN: 460682600) and primary practice location at 27284-3776.

Javaid's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 617 traditional Medicare patients, billed 8,201 HCPCS/CPT codes, and received $240,648 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,603 prescription claims across 639 beneficiaries totaling $1,020,594 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 3,019 claims. Open Payments data shows 88 records totaling $17,213. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $385,388 to $1,020,594. For DME billing, reported payments did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	431	2,444	$190,134
2016	467	2,495	$177,168
2017	510	2,628	$189,615
2018	564	4,260	$250,537
2019	575	6,268	$265,187
2020	557	5,128	$220,318
2021	572	4,867	$214,646
2022	575	3,909	$198,799
2023	607	3,479	$202,436
2024	617	8,201	$240,648

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	309	1,689	$385,388
2016	324	1,922	$677,082
2017	393	2,217	$714,343
2018	383	1,557	$508,414
2019	451	2,129	$757,418
2020	383	1,641	$777,851
2021	421	1,784	$842,889
2022	468	1,886	$986,797
2023	537	2,276	$871,625
2024	639	2,603	$1,020,594

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	753	2,160	$171,546
2016	832	2,601	$118,942
2017	900	2,464	$142,044
2018	916	2,509	$196,383
2019	1,134	2,896	$126,358
2020	1,092	3,050	$165,731
2021	886	2,261	$99,616
2022	676	2,070	$123,774
2023	803	2,116	$130,657
2024	1,137	3,019	$210,206

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	173	173	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	472	834	$87
94729	Test to examine how well the lungs exchange gases	269	288	$39
94727	Test to determine lung volumes using gas dilution or washout	270	289	$32
94375	Test to measure rate of airflow	250	395	$27

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	353	14,910	$315,192
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	205	8,720	$156,345
Breo Ellipta	Fluticasone/Vilanterol	160	5,400	$69,810
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	13	364	$65,820
Symbicort	Budesonide/Formoterol Fumarate	152	7,200	$55,526

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	34	$26,067
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	19	$19,401
A7031	Face mask interface, replacement for full face mask, each	N	91	204	$18,532
A7030	Full face mask used with positive airway pressure device, each	N	95	220	$17,442
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	31	211	$16,922

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	86	$1,723	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$15,490	Mylan Specialty L.P.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adnan A. Javaid, M.D.?

Tedicare shows public-source Medicare data for Adnan A. Javaid, M.D. (NPI 1881879310), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adnan A. Javaid, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adnan A. Javaid, M.D.?

Adnan A. Javaid, M.D. is linked to LUNG AND SLEEP WELLNESS CENTER PC (billing NPI 1366790594) in the available physician profile data.

Does Adnan A. Javaid, M.D. have Open Payments data?

Adnan A. Javaid, M.D. has 88 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.